Rock Springs Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Rock Springs Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,031,550	Closed	-$111M	–	126
2023 Q1	$111M	Hold	1,031,550	–	–	2.64%	10
2022 Q4	$113M	Buy	1,031,550 +386,143	+60%	+$25M	2.73%	8
2022 Q3	$38.1M	Buy	645,407 +900	+0.1%	+$41.2K	0.98%	37
2022 Q2	$18.2M	Buy	644,507 +20,200	+3%	+$585K	0.53%	57
2022 Q1	$23.6M	Buy	624,307 +5,900	+1%	+$233K	0.59%	57
2021 Q4	$24.5M	Buy	618,407 +8,271	+1%	+$259K	0.56%	57
2021 Q3	$14.5M	Buy	610,136 +14,040	+2%	+$331K	0.3%	86
2021 Q2	$14.6M	Buy	596,096 +21,238	+4%	+$474K	0.29%	91
2021 Q1	$10.5M	Buy	+574,858	New	+$11.9M	0.23%	109

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Rock Springs Capital Management's RXDX Position: Q2 2023 in Review

Rock Springs Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 1,031,550 shares — an estimated $111M sold.

Rock Springs Capital Management first reported a position in RXDX in Q1 2021 and held it in 9 quarters. The position peaked at $113M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Rock Springs Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Rock Springs Capital Management sold 1,031,550 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $111M.
Rock Springs Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Rock Springs Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $113M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Rock Springs Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.